Zobrazeno 1 - 10
of 476
pro vyhledávání: '"Marc E, Lippman"'
Autor:
Melinda Magna, Gyong Ha Hwang, Alec McIntosh, Katherine Drews-Elger, Masaru Takabatake, Adam Ikeda, Barbara J. Mera, Taekyoung Kwak, Philip Miller, Marc E. Lippman, Barry I. Hudson
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-15 (2023)
Abstract Triple-negative breast cancer (TNBC) is a highly aggressive and metastatic cancer subtype, which is generally untreatable once it metastasizes. We hypothesized that interfering with the Receptor for Advanced Glycation End-products (RAGE) sig
Externí odkaz:
https://doaj.org/article/f18933caaf174985b1637813da6ec4ae
Stay on top of the latest knowledge in the field with this must-have resource for all clinicians who treat breast diseases. Expand your knowledge of every aspect of breast diseases as a diverse and distinguished group of internationally-recognized ex
Autor:
Chloe J. Taub, Alain Diaz, Bonnie B. Blomberg, Devika R. Jutagir, Hannah M. Fisher, Lisa M. Gudenkauf, Marc E. Lippman, Barry I. Hudson, Michael H. Antoni
Publikováno v:
Psychosomatic medicine. 84(7)
Elevated inflammation and psychological distress in patients with breast cancer (BCa) have been related to poorer health outcomes. Regulation of the hypothalamic-pituitary-adrenal axis and signaling of the receptor for advanced glycation end products
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16b090d75b42d1c86132eb312df17a31
https://pubmed.ncbi.nlm.nih.gov/35980780
https://pubmed.ncbi.nlm.nih.gov/35980780
Supplemental Figure 2. HACE1 overexpression reduces activated Rac1 and attenuates ccRCC growth and survival. (A) Rac1 and HACE1 mRNA expression correlation from the KIRC TCGA Dataset (B) Rac1-GTP Pull-down assay of empty vector or HACE1 overexpressin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0e065093048929aa8b49bdcf2a058b6
https://doi.org/10.1158/1535-7163.22520848
https://doi.org/10.1158/1535-7163.22520848
Autor:
Marc E. Lippman, Adriana De La Garza, Dayrelis T. Mesa Lopez, Pallavi Chaturvedi, Erik T. Goka
Figure S5. HCT116 cells were treated with different dose of 5FU (6.25, 12.5, 25 μM) for 72hrs. The cells were lysed in RIPA lysis buffer. 50 μg of protein was resolved on SDS-PAGE gel, transferred on the nitrocellulose member. The membrane was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d1ec56dc1b853d3f85883a88fb51f76
https://doi.org/10.1158/1535-7163.22510681
https://doi.org/10.1158/1535-7163.22510681
Autor:
Marc E. Lippman, Adriana De La Garza, Dayrelis T. Mesa Lopez, Pallavi Chaturvedi, Erik T. Goka
Resistance to chemotherapy represents a major limitation in the treatment of colorectal cancer. Novel strategies to circumvent resistance are critical to prolonging patient survival. Rac1b, a constitutively activated isoform of the small GTPase Rac1,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ae18a6ed14a9f18a462950fdfc154ed
https://doi.org/10.1158/1535-7163.c.6539680
https://doi.org/10.1158/1535-7163.c.6539680
Clear cell renal cell carcinoma (ccRCC) remains a common cause of cancer mortality. Better understanding of ccRCC molecular drivers resulted in the development of antiangiogenic therapies that block the blood vessels that supply tumors with nutrients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2adcd074a0df5b1e87a152d210b5b1b0
https://doi.org/10.1158/1535-7163.c.6542812.v1
https://doi.org/10.1158/1535-7163.c.6542812.v1
Supplementary Figure 2. Cellular proliferation assay of VCaP cells expressing either control shRNA (shNSC) or two independent HACE1 shRNAs (shHACE1 1 and shHACE1 2).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::208c4bab7fb4278513829976026de957
https://doi.org/10.1158/1535-7163.22522675.v1
https://doi.org/10.1158/1535-7163.22522675.v1
Supplemental Figure 3. In vitro and In Vivo characterization of GYS32661. (A) Cellular proliferation assay of 786-O cells treated with vehicle, 2.5, and 5 μM GYS32661. (B) Plasma and tumor concentrations of GYS32661 at 0.25, 1, 4, and 8 hour t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26163115917bc2a151f9a1f56b5c33a1
https://doi.org/10.1158/1535-7163.22520845.v1
https://doi.org/10.1158/1535-7163.22520845.v1
Table S1 from RAC1b Overexpression Confers Resistance to Chemotherapy Treatment in Colorectal Cancer
Autor:
Marc E. Lippman, Adriana De La Garza, Dayrelis T. Mesa Lopez, Pallavi Chaturvedi, Erik T. Goka
Table S1 Shows Rac1 Immunohistochemistry scores for normal colon and colon cancer by stage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c49876a3ff83078927dd63f56835f87
https://doi.org/10.1158/1535-7163.22510672.v1
https://doi.org/10.1158/1535-7163.22510672.v1